Compare Nu Holdings Ltd (NU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Viatris Inc — how do they compare? Nu Holdings Ltd trades at $15.45 (market cap $75.26B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Nu Holdings Ltd is far larger — about 3.7× Viatris Inc's market cap, and Viatris Inc pays a 2.74% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and Viatris Inc for 57 Days on average.
| NU | VTRS | |
|---|---|---|
Market Cap | $75.26B | $20.12B |
Volume | 82,363,718 | 7,543,511 |
Sector | Financials | Health |
52-Week High | $18.76 | $18.27 |
52-Week Low | $11.60 | $9.74 |
Typical Hold Time | 53 Days | 57 Days |
Enterprise Value | $97.88B | $32.24B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings trades at $15.38, down 1.79% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income reaching $2.9B. Recent news highlights market volatility around potential acquisition rumors, though the company has denied pursuing a Monzo deal.
The outlook remains positive with analyst consensus favoring Buy ratings (56.52%) and a $16.53 price target suggesting 7.5% upside. Key risks include credit quality concerns from expanding lending operations and high customer concentration. Revenue growth and profitability trends support continued investor interest despite recent earnings misses.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue trends show a slight decline from $16.3B in 2022 to $14.3B in 2025, but net losses have widened significantly, reaching -$3.51B in 2025. Positive cash flow generation and a dividend payment scheduled for September 2026 highlight financial stability amid profitability challenges.
The outlook for VTRS is mixed; analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside, supported by strong cash flow and recent product approvals. However, persistent net losses, high P/E ratio of 236.2, and substantial long-term debt of $14.04B pose risks. Investors should weigh the potential for operational turnaround against ongoing profitability concerns and competitive pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
